107279987937751585

A Happy Pill for Some Biotechs
Analysts predict 2003’s rally will continue, with the winners changing to include a few blue-chip names and select up-and-comers.

107279980233861227

Biotech: A Coming Boom — or Bust?
Two industry veterans lay out contrasting views about what the sector and its investors can expect over the next 12 months.

107220074852044258

Biotech may be poised for “big year”
Biotechnology is poised for a boom year in 2004, wrapping up 2003 with a strong recovery and plenty of reason for optimism, in the forecast of G. Steven Burrill, chief executive officer of the San Francisco-based life sciences merchant bank, Burrill & Co.

107176228631622890

Got Life?
Corporate lawyers haven’t had much to celebrate since the Internet bubble burst, but a recent stock market run on life sciences companies is breathing new buoyancy into some practices.

107172880604229265

When Patents Persist
What if that patent you’re paying royalties on suddenly gets extended? Have you negotiated the best licensing deal possible?

107158609334708868

Amgen’s Cannibalistic Ways
If you don’t think that Amgen is excited about its future, check out what the company is piling on its plate. The biotech giant will be earmarking half of next year’s revenue to launch a $5 billion share buyback.

107151173637091907

FDA Chief Eyes Path for Copycat Biotech Drugs
Food and Drug Administration Commissioner Mark McClellan said on Friday it may be justifiable for regulators to approve generic forms of biotech drugs even if they have not been through the same lengthy clinical trials required of the original drugs.

107151163734311721

Boston’s Biotech Moment
The future is moving out of dusty library stacks and into pristine laboratories on both sides of the Charles River, making this area the national leader in biotechnology. The boom is driven by a new breed of intellectual wearing a white lab coat and using science to breach the barrier between academia and commerce.

107136344432075449

Professor, Biotech Butt Heads
Ignacio Chapela, an ecologist known for his controversial research on genetically modified corn, is turning a career setback into a call for action among scientists opposed to the influence of corporate interests on academic research.
Chapela, who was denied tenure last month at the University of California at Berkeley, is now accusing the institution of trying to please the biotech industry by shutting him out.

107124594809632918

Tech Transfer: The Ties That Bind
Did you know that the lack of an IPO window, depressed market conditions and a downturn in venture financing affect not only companies but also universities? That’s because so many academic institutions are tied to the fortunes of companies, both small and large, through their technology transfer agreements.